References
- Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11.
- Lamprecht P, Gross WL. Wegener's granulomatosis. Herz. 2004; 29(1):47–56.
- Hagen EC, Daha MR, Hermans JO, Andrassy K, Csernok E, Gaskin G, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int. 1998;53(3):743–53.
- Pankhurst T, Savage COS, Gordon C, Harper L. Malignancy is increased in ANCA-associated vasculitis. Rheumatology. 2004;43(12):1532–5.
- Heijl C, Harper L, Flossmann O, Stücker I, Scott DGI, Watts RA, et al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis. 2011;70(8):1415–21.
- Knight A, Askling J, Ekbom A. Cancer incidence in a population‐based cohort of patients with Wegener's granulomatosis. Int J Cancer. 2002;100(1):82–5.
- Araki R, Shima T, Goto H, Imoto I, Baba M, Misaki M, Suzuki S. Wegener's granulomatosis with papillary adenocarcinoma of the thyroid. Intern Med (Tokyo, Japan). 1992;31(8):1065–8.
- Jeong YG, Kim TH, Lee CM, Shim KS, Moon IK, Lee SI, et al. A case of limited Wegener's granulomatosis with gastroenteritis and mesenteric lymphadenopathy. Korean J Gastroenterol. 2010;55(5):331–5.
- Kermani TA, Warrington KJ, Amin S. Malignancy risk in vasculitis. Ther Adv Musculoskel Dis. 2011;3(1):55–63.
- Hoff M, Rodevand E. Development of multiple malignancies after immunosuppression in a patient with Wegener's granulomatosis. Rheumatol Int. 2005;25(3):238–40.
- Edgar JDM, Rooney DP, Mc Namee P, Mc Neill TA. An association between ANCA positive renal disease and malignancy. Clin Nephrol. 1993;40(1):22–5.
- Matteson EL, Abu-Hilal MA. Rheumatic manifestations in malignancy. Curr Rheumatol Rev. 2008;4(1):50–8.
- Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009;6(11):638–47.
- Faurschou M, Sorensen IJ, Mellemkjaer L, Loft AGR, Thomsen BS, Tvede N, Baslund B. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol. 2008;35(1):100–5.
- Villa ML, Mukherjee JJ, Tran NQ, Cheah WK, Howe HS, Lee KO. Anaplastic thyroid carcinoma with destructive thyrotoxicosis in a patient with preexisting multinodular goiter. Thyroid. 2004;14(3):227–30.
- Miyahara H, Sato T, Ueda G, Okudaira Y. A case of Wegener's granulomatosis with cancers of the thyroid gland and the cervix uteri (author's transl)]. Nihon Jibiinkoka Gakkai kaiho. 1976;79(11): 1368–74.
- Lim C, Mahar A, Clark JR, McGuigan L, Felbel W, Murali R. Concurrent involvement of thyroid gland by Wegener's granulomatosis and papillary thyroid carcinoma. Pathology. 2011;43(4):381–3.
- Tanaka A, Maeda K, Sawai K, Okuda J, Sugawara A, Kuwahara T. Concealed hypothyroidism in patients with myeloperoxidase antineutrophili cytoplasmic autoantibodies-(MPO-ANCA) positive renal disease. Clin Nephrol. 1999;52(2):91–5.
- Stone JH. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum. 2003;48(8):2299–309.
- Belfiore A, Russo D, Vigneri R, Filetti S. Graves’ disease, thyroid nodules and thyroid cancer. Clinical endocrinology. 2001;55(6):711–8.
- Repplinger D, Bargren A, Zhang Y-W, Adler JT, Haymart M, Chen H. Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer?J Surg Res. 2008;150(1):49–52.
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin.2011;61(2):69–90.
- Al-Shukaili AK, Al-Jabri AA, Al-Moundhri MS. Prognostic value of auto-antibodies in the serum of Omani patients with gastric cancer. Saudi Med J. 2006;27(12):1873–7.
- Ma X. Epidemiology of myelodysplastic syndromes. Am J Med. 2012; 125(7 Suppl):S2–5.
- Pirayesh A, Verbunt R, Kluin PH, Meinders AE, De Meijer P. Myelodysplastic syndrome with vasculitic manifestations. J Intern Med. 2003;242(5):425–31.
- Savige JA, Chang L, Smith CL, Duggan JC. Anti‐neutrophil cytoplasmic antibodies (ANCA) in myelodysplasia and other haematological disorders. Aust N Z J Med. 1994;24(3):282–7.
- Billstrom R, Johansson H, Johansson B, Mitelman F. Immune-mediated complications in patients with myelodysplastic syndrome-clinical and cytogenetic features. Eur J Haematol. 1995;55(1):42–8.
- Das PM, Sinqal R. DNA methylation and cancer. J Clin Oncol. 2004;22(22):4632–42.
- Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O'Keefe C, et al. Aberrent DNA methylation is a dominant mechanism in MDS progression to AML. Blood.2009;113(6):1315–25.
- Ciavatta DJ, Yang J, Preston GA, Badhwar AK, Xiao H, Hewins P, et al. Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J Clin Invest. 2010;120(9): 3209–19.